Cognitive functioning in a cohort of high-grade glioma patients
By:
References
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114: 97–109. doi: 10.1007/s00401-007-0243-4
- Smrdel U, Popovic M, Zwitter M, Bostjancic E, Zupan A, Kovac V, et al. Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor. Radiol Oncol 2015; 50: 394–401. doi: 10.1515/raon-2015-0041
- Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D, et al. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochir 2016; 158: 1943–53. doi: 10.1007/s00701-016-2928-8
- Kurdi M, Shafique Butt N, Baeesa S, Alghamdi B, Maghrabi Y, Bardeesi A, et al. The impact of IDH1 mutation and MGMT promoter methylation on recurrence-free interval in glioblastoma patients treated with radiotherapy and chemotherapeutic agents. Pathol Oncol Res 2021; 27: 1609778. doi: 10.3389/pore.2021.1609778
- Sinha R, Stephenson JM, Price SJ. A systematic review of cognitive function in patients with glioblastoma undergoing surgery. Neuro-oncology Pract 2020; 7: 131–42. doi: 10.1093/nop/npz018
- Van Kessel E, Emons MAC, Wajer IH, Van Baarsen KM, Broekman ML, Robe PA, et al. Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment. Neuro-Oncology Pract 2019; 6: 463. doi: 10.1093/nop/npz008
- Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurology 2004; 3: 159–68. doi: 10.1016/S1474-4422(04)00680-5
- Jütten K, Mainz V, Gauggel S, Patel HJ, Binkofski F, Wiesmann M, et al. Diffusion tensor imaging reveals microstructural heterogeneity of normal-appearing white matter and related cognitive dysfunction in glioma patients. Front Oncol 2019; 9: 536. doi: 10.3389/fonc.2019.00536
- Van Kessel E, Snijders TJ, Anniek ·, Baumfalk E, Ruis C, Van Baarsen KM, et al. Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study. J Neurooncol 2020; 146: 97–109. doi: 10.1007/s11060-019-03341-6
- Meyers CA, Hess KR. Neuro-oncology multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-Oncology2003; 5: 89–95. doi: 10.1093/neuonc/5.2.89
- Armstrong CL, Goldstein B, Shera D, Ledakis GE, Tallent EM. The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence. Cancer 2003; 97: 649–56. doi: 10.1002/cncr.11099
- Flechl B, Sax C, Ackerl M, Crevenna R, Woehrer A, Hainfellner J, et al. The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. Radiother Oncol 2017; 125: 228–33. doi: 10.1016/j.radonc.2017.07.027
- Johnson DR, Sawyer AM, Meyers CA, Patrick B, Neill O’, Wefel JS. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol 2012; 14: 808–16. doi: 10.1093/neuonc/nos082
- Meyers CA, Hess KR, Yung WKA, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000; 18: 646–50. doi: 10.1200/JCO.2000.18.3.646
- Lee ST, Park CK, Kim JW, Park MJ, Lee H, Lim JA, et al. Early cognitive function tests predict early progression in glioblastoma. Neuro-oncology Pract 2015; 2: 137–43. doi: 10.1093/nop/npv007
- Butterbrod E, Synhaeve N, Rutten GJ, Schwabe I, Gehring K, Sitskoorn M. Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients. J Neurooncol 2020; 149: 103–11. doi: 10.1007/s11060-020-03577-7
- Derks J, Kulik S, Wesseling P, Numan T, Hillebrand A, van Dellen E, et al. Understanding cognitive functioning in glioma patients: the relevance of IDH-mutation status and functional connectivity. Brain Behav 2019; 9: e01204.doi: 10.1002/brb3.1204
- van Kessel E, Snijders TJ, Baumfalk AE, Ruis C, van Baarsen KM, Broekman ML, et al. Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study. J Neurooncol 2020; 146: 97–109. doi: 10.1007/s11060-019-03341-6
- Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol 2016; 18: 1656–63. doi: 10.1093/neuonc/now165
- Bunevicius A, Miller J, Parsons M. Isocitrate dehydrogenase, patient-reported outcomes, and cognitive functioning of glioma patients: a systematic review. Curr Oncol Rep 2020; 22: 120. doi: 10.1007/s11912-020-00978-9
- Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, et al. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2019; 20: 1444–53. doi: 10.1016/S1470-2045(19)30502-9
- Wang Q, Xiao F, Qi F, Song X, Yu Y. Risk factors for cognitive impairment in high-grade glioma patients treated with postoperative radiochemotherapy. Cancer Res Treat 2020; 52: 586–93. doi: 10.4143/crt.2019.242
- Herzog A. [Validity and reliability of the new Slovenian Test of Word Learning]. [Slovenian]. [graduation thesis]. Ljubljana: Universty of Ljubljana; 2015.
- Remšak T. [Development of the Spelling Fluency Test]. [Slovenian]. [graduation thesis]. Ljubljana: Universty of Ljubljana; 2013.
- Sánchez-Cubillo I, Periáñez JA, Adrover-Roig D, Rodríguez-Sánchez JM, Ríos-Lago M, Tirapu J, et al. Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc 2009; 15: 438–50. doi: 10.1017/S1355617709090626
- Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011; 12: 703–8. doi: 10.1016/S1470-2045(10)70294-1
- Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, et al. Molecular biomarker-defined brain tumors: epidemiology, validity, and completeness in the United States. Neuro Oncol 2022; 24: 1989–2000. doi: 10.1093/neuonc/noac113
- Capper D, Mittelbronn M, Meyermann R, Schittenhelm J. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol 2008; 115: 249–59. doi: 10.1007/s00401-007-0310-x
- Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 2000; 47: 324–33. doi: 10.1097/00006123-200008000-00011
- Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neurooncol 2017; 131: 565–74. doi: 10.1007/s11060-016-2328-1
- Van Kessel E, Snijders TJ, Anniek·, Baumfalk E, Ruis C, Van Baarsen KM, et al. Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study. J Neurooncol 2020; 146: 97–109. doi: 10.1007/s11060-019-03341-6
Language: English
Page range: 201 - 210
Submitted on: Nov 29, 2022
Accepted on: Dec 31, 2022
Published on: Jun 21, 2023
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2023 Andreja Cirila Skufca Smrdel, Anja Podlesek, Marija Skoblar Vidmar, Jana Markovic, Jana Jereb, Manja Kuzma Okorn, Uros Smrdel, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.